Summary. It has been suggested that endothelial apoptosis is a primary lesion in the pathogenesis of thrombotic thrombocytopenic purpura (TTP). We tested this hypothesis by examining the phenotypic signatures of endothelial microparticles (EMP) in TTP patients. In addition, the effect of TTP plasma on microvascular endothelial cells (MVEC) in culture was further delineated. EMP released by endothelial cells (EC) express markers of the parent EC; EMP released in activation carry predominantly CD54 and CD62E, while those in apoptosis CD31 and CD105. We investigated EMP release in vitro and in TTP patients. Following incubation of MVEC with TTP plasma, EMP and EC were analysed by flow cytometry for the expression of CD31, CD51, CD54, CD62E, CD105, CD106 and von Willebrand factor (VWF) antigen. EMP were also analysed in 12 TTP patients. In both EC and EMP, CD62E and CD54 expression were increased 3-to 10-fold and 8-to 10-fold respectively. However, CD31 and CD105 were reduced 40-60% in EC but increased twofold in EMP. VWF expression was found in 55 ± 15% of CD62E + EMP. Markers of apoptosis were negative. In TTP patients, CD62E
10-fold and 8-to 10-fold respectively. However, CD31 and CD105 were reduced 40-60% in EC but increased twofold in EMP. VWF expression was found in 55 ± 15% of CD62E + EMP. Markers of apoptosis were negative. In TTP patients, CD62E
+ and CD31 + /CD42b ) EMP were markedly elevated, and preceded and correlated well with a rise in platelet counts and a fall in lactate dehydrogenase. CD62E + EMP (60 ± 20%) co-expressed VWF and CD62E. The ratio of CD31 + /42b ) to CD62E + EMP exhibited a pattern consistent with activation. In conclusion, our studies indicate endothelial activation in TTP. EMP that co-express VWF and CD62E could play a role in the pathogenesis of TTP.
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In thrombotic thrombocytopenic purpura (TTP) intravascular platelet adhesion, aggregation and formation of platelet rich thrombi in microvasculature lead to severe thrombocytopenia, microangiopathic haemolytic anaemia and multiple organ dysfunction (Ridolfi & Bell, 1981; Ruggenenti & Remuzzi, 1996; Moake, 2002) . Moake (1986 Moake ( , 2002 reported unusually large von Willebrand factor multimers (ULVWFM) in patients with relapsing TTP and suggested that ULVWFM released from disturbed endothelia play a pivotal role in TTP, promoting platelet adhesion and aggregation in the microvasculature. This observation supported the theory that endothelial injury is the primary lesion in the pathogenesis of TTP (Ridolfi & Bell, 1981) . However, the detailed nature of the endothelial lesion in TTP remains to be elucidated.
We previously demonstrated ) that plasma from patients with acute TTP, when incubated with brain or renal microvascular endothelial cells (MVEC), induced expression of endothelial adhesins such as vascular cell adhesion molecule-1 (VCAM-1, CD106) and intracellular adhesion molecule-1 (ICAM-1, CD54), and promoted release of endothelial microparticles (EMP), small membrane-derived vesicles ([1AE0 lm) shed from disturbed endothelium. EMP carry antigens, such as platelet-endothelial cell adhesion molecule-1 (PECAM-1, CD31) and vitronectin receptor (CD51), of the parent EC, which can be detected by flow cytometry, employing antibodies specific to these antigens (Combes et al, 1999; Jimenez et al, 2001 . For example, during activation, EMP bearing inducible markers such as CD62E and CD54 were increased, in parallel with increased expression of these antigens on the parent EC. In contrast, in apoptosis, EMP expressed predominantly constitutive markers such as CD31 and CD105, with a concomitant depletion of such antigens on the parent EC. Thus, assay of a selected panel of antigenic markers on EMP could discriminate the nature of endothelial lesion, such as state of activation versus apoptosis. Patient and control populations. This study was based on data from 12 patients admitted to the University of Miami Medical Centre with a diagnosis of TTP. Approval by the Institutional Review Board of the University of Miami School of Medicine was obtained and all patients gave informed consent. Criteria for the diagnosis of TTP have been previously described (Ahn et al, 1996) . Briefly, all patients with TTP presented with the following findings: severe thrombocytopenia (platelet count <20 · 10 9 /l), microangiopathic haemolytic anaemia, elevated lactate dehydrogenase (LDH) level and neurological dysfunction. As patient controls, 10 patients with chronic idiopathic thrombocytopenic purpura (ITP) were recruited. All had suffered chronic thrombocytopenia for over a year without any known underlying causes and had previously responded to glucocorticoids; bone marrow studies showed increased megakaryocyte counts, consistent with ITP. Normal control plasma was obtained from 10 healthy volunteers.
MATERIALS AND METHODS

Antibodies
Sample preparation for clinical studies. Blood samples were collected in 5 ml sodium citrate tubes and were centrifuged 10 min at 160 g to prepare platelet-rich plasma (PRP). The PRP was further centrifuged 6 min at 1500 g to obtain platelet-poor plasma (PPP). PPP was prepared and assayed for EMP within 4 h of venepuncture. Aliquots of PPP (30 ll) in 12 · 75 mm polypropylene tubes were used to measure EMP as follows: (a) to measure CD62E + EMP, PPP was incubated with 5 ll of PE-labelled anti-CD62E; (b) to measure CD31 + /CD42b ) EMP, PPP was incubated with 5 ll each of PE-labelled anti-CD31 and FITC-labelled anti-CD42b. The purpose of the anti-CD42b was to exclude platelet microparticles (PMP), as explained previously . Hereafter, these EMP are called simply CD31 + EMP. After a 20 min incubation at room temperature with gentle shaking (orbital shaker, 120 rpm), 0AE5 ml of phosphate-buffered saline (PBS) was added and EMP were analysed by flow cytometry (Coulter EPICS XL, Beckman Coulter, Miami, FL, USA), essentially as previously described .
Sample preparation for study of effect of TTP plasma on EC culture. Renal and brain MVEC (Cell Systems Corporation, Kirkland, WA, USA) were cultured and treated as previously described . Briefly, cells were resuspended in culture medium (Cell Systems) and replated in 12-well tissue culture multiwell clusters (Corning, Costar Corporation, Cambridge, MA, USA) precoated with attachment factor (Cell Systems) at a density of 1 · 10 5 /well 48 h prior to experiments. Then, 200 ll of TTP or control plasmas were added to each well containing 1AE0 ml media and maintained for 24 h. All plasmas were frozen at )70°C and filtered through a 0AE1 lm filter (Whatman, Clifton, NJ, USA) immediately before use to eliminate 95% of detectable pre-existing EMP. As positive controls, renal and brain MVEC were cultured in the presence of 10 ng/ml of tumour necrosis factor-a (TNF-a; Sigma), or deprived of growth factors (GFD), for 24 h. These conditions have been shown to induce activation and apoptosis, respectively (Pober et al, 1986; Hogg et al, 1999) , and were confirmed in our laboratory Jy et al, 2002a) . EMP in the supernatants were then measured by incubation of a 1:10 dilution with either anti-human CD31, CD54, CD62E, CD105, or anti-VWF:Ag. As no platelets were present in the culture, it was not necessary to use CD42b for in vitro experiments. Samples were then processed as described above for in vivo samples. Conversion of raw counts of EMP, given on the flow cytometer, to units of EMP per millilitre of original supernatant was calculated as previously described .
Detection of surface markers on EC. The above antigenic markers were also applied to the remnant EC. After supernatants were removed for testing, each plate was incubated with 10 ll of the above monoclonal antibodies for 30 min, then excess antibody was removed and the EC were washed three times with 1 ml of complete basal medium. The cells were then detached by addition of trypsin (Gibco Invitrogen, Carlsbad, CA, USA) (0AE4 ml of 0AE05% trypsin/0AE53 mmol/l EDTA). After 3-5 min, the trypsin was neutralized with 0AE3 ml of fetal bovine serum and the resulting 1:1 suspension of MVEC was examined by flow cytometry to measure fluorescent expression.
Statistical analysis. Student's t-test was used to evaluate significance between pairs of groups. In cases where the data failed the Kolmogorov-Smirnov normality test, the Mann-Whitney rank sum test was used. Statistical significance was defined as P < 0AE05. All data analyses were performed using the software Sigmaplot 4AE0 and Statmost.
RESULTS
Effect of TTP plasma on EMP and remnant whole EC in cultures. GFD-induced apoptosis in MVEC, as indicated by TUNEL (terminal deoxynucleotidyl transferase mediated dUTP nick end labelling) positivity, and viability by trypan blue was 72 ± 12% and 8 ± 3% for renal MVEC, and 53 ± 12% and 15 ± 4% for brain MVEC respectively. Exposure of MVEC to TNF-a did not result in apoptosis as indicated by TUNEL positivity of <2% and viability of >93% for all cultures, confirming our previous reports Jy et al, 2002a) . Figure 1 summarizes the data on immunophenotypes of renal EC (Fig 1A,B) and the EMP counts (Fig 1C,D) . Figure 1A shows that constitutive markers CD31 and CD105 on whole EC were substantially reduced in GFD when compared with untreated EC (Unt), while the EMP bearing these markers were greatly increased by GFD treatment (Fig 1C) . However, as shown in Fig 1B, inducible markers CD54 and CD62E on the parent EC were increased by activation (TNF-a) but not by apoptosis (GFD), and likewise, the EMP released (Fig 1D) . When these results were compared with those from plasma treatments, it was seen that TTP plasma from the acute stage (TTP-A) induced a phenotypic signature consistent with activation, not apoptosis, because of the expression of inducible markers on the EC surface and EMP (Fig 1B,D) . Note that plasma from TTP patients in remission (TTP-R) had no such effect; nor did exposure to plasma from ITP patients or normal controls. Although CD31 + and CD105 + EMP were increased moderately by TTP plasma (Fig 1C) , this effect was only marginally greater than that of TNF-a and the TTP plasma caused no decrease in CD105 surface expression (Fig 1A) . We previously found a ratio of CD62E + to CD31 + EMP of >4AE0 in activation and <0AE4 in apoptosis . In the present study, this ratio was 5AE6 for MVEC stimulated with TTP plasma.
The above studies were conducted with renal MVEC. We also investigated brain MVEC by the same experiments and obtained data comparable with that given above (not shown).
EMP in TTP patients
Data on a representative patient are plotted in Fig 2A, together with the platelet counts ( Fig 2B) and LDH (Fig 2C) . All patients tested presented similar EMP patterns. It should be noted that both measures of EMP returned to normal after remission was achieved on day 18 (Fig 2) .
As shown in Fig 3, . Results for whole EC are given as mean fluorescent intensity while those for EMP are counts ( · 10 6 /ml). Constitutive markers are depicted on the left, while inducible are located on the right. UNT, untreated controls; GFD, growth factor deprivation; TNF, tumour necrosis factor-a; CP, control plasma (n ¼ 10); TTP(A), TTP plasma, acute phase (n ¼ 10); TTP(R), TTP plasma, remission (n ¼ 10); ITP, ITP plasma, active phase (n ¼ 10). Values shown are the means of three experiments (±SD) (*P < 0AE0001, **P ¼ 0AE01).
sharply after the first treatment and thereafter declined steadily (Fig 4) .
Association of VWF with EMP
As shown in Fig 5A, supernatants from cultured renal MVEC stimulated with plasma from five TTP patients yielded EMP that co-expressed VWF with CD62E at a level about 15-fold that of five normal controls. Figure 5B shows corresponding EMP plasma results in five TTP patients and five controls: VWF co-expressed with CD62E on EMP in the plasma of TTP patients was about fivefold of that found in normal control plasma.
DISCUSSION
Endothelial dysfunction plays a central role in the pathogenesis of many thrombotic and inflammatory disorders (Wu & Thiagarajan, 1996) . However, existing laboratory tests to define or monitor endothelial disturbances in the clinical setting are limited. We have reported elevated CD31 + /CD42b ) EMP in patients in active phases of TTP and multiple sclerosis (MS), and observed that the levels decreased to normal in remission Minagar et al, 2001) . We have also reported elevated EMP in pre-eclampsia, acute coronary syndromes and malignant hypertension (Bernal-Mizrachi et al, 2003; GonzalezQuintero et al, 2003; Preston et al, 2003) . Others have reported elevated EMP in patients with lupus anti-coagulant, coronary artery disease and diabetes mellitus (Combes et al, 1999; Mallat et al, 2000; Boulanger et al, 2001; Sabatier et al, 2002a) . Clinical applications of an EMP assay show promise for monitoring endothelial injury in thrombotic and inflammatory disorders. We and others have shown that EMP are heterogeneous, as defined by antigenic phenotypes, and that their relative abundance and phenotype reflects the nature of the EC injury (Combes et al, 1999; Jimenez et al, 2001 Jimenez et al, , 2003 . In addition, EMP express tissue factor (TF) and provide a phospholipid surface, indicating procoagulant potential (Combes et al, 1999; Jimenez et al, 2001) . Further investigation of + and CD62E + EMP were measured (±SD) on admission and when remission was achieved. Similar EMP patterns were observed in 10 patients with TTP. EMP counts correlated well with platelet counts (B) and LDH levels (C). Results are expressed as means of three measurements per time period.
the mechanisms of generation and functional characteristics of EMP in different disorders involving endothelial perturbation could lead to the improved understanding of the endothelial lesion in specific vascular, thrombotic and inflammatory conditions. Endothelial injury is believed to be the primary underlying lesion in TTP, initiating intravascular platelet adhesion, aggregation and formation of platelet rich thrombi in microvasculature (Ridolfi & Bell, 1981) . However, the precise nature of the endothelial lesion in TTP is poorly understood. It has been reported that TTP plasma induced apoptosis of EC derived from brain, renal, or dermal microvascular origin, but not EC derived from larger vascular beds (Laurence et al, 1996; Mitra et al, 1997) . Thus, its has been argued that apoptosis may be the principal endotheliopathy in TTP (Laurence et al, 1996; Mitra et al, 1997 Mitra et al, , 1998 .
In the present study, we investigated the phenotypic profiles of EMP that were released upon incubation of TTP plasma with EC in vitro as well as EMP in blood samples from patients with acute TTP. Our previous studies showed that CD62E and CD31 are the most useful markers of EMP found to date. In activation, CD62E + EMP are the most abundant, while in apoptosis, CD31 + EMP predominate. Accordingly, the ratio of CD62 + EMP to CD31 + EMP provides a useful measure for discriminating a state of endothelial activation from apoptosis: this ratio is high in activation, low in apoptosis . This conclusion was based on findings obtained with TNF-a, a known activator, and deprivation of growth factor, conditions known to induce apoptosis (Pober et al, 1986; Hogg et al, 1999) .
When plasma from TTP patients was incubated with MVEC, TTP plasma induced release of EMP expressing predominantly CD62E, hence the CD62E/CD31 ratio was consistent with endothelial activation, not apoptosis. Parallel clinical studies (in vivo) on EMP in TTP patients revealed that CD62 + EMP were more abundant than CD31 + EMP, indicating that EMP in TTP are released from ) and CD62E + were significantly elevated in TTP patients when compared with controls. Error bars show ±SD (*P < 0AE0001). ) and CD62E + EMP in TTP patients pre-and post-plasmapheresis. EMP were measured pre-and post-plasmapheresis in three patients with TTP. Both CD31 + / CD42b
) and CD62E + EMP decreased sharply after the first plasmapheresis, thereafter more gradually after each plasma exchange. Data were obtained upon admission and reflected the first 5 d of treatment (±SD). activated, not apoptotic, EC. Praprotnik et al (2001) recently reported that stimulation of EC with TTP plasma resulted in a state of endothelial activation.
The present report also includes data on EMP pre-and post-plasmapheresis. Interestingly, all four patients for whom this data were available showed a dramatic drop in EMP after the first treatment; thereafter, a more gradual reduction after each plasma exchange was observed. It is possible that the first plasmapheresis may remove large quantities of thrombogenic EMP accumulated in the circulation while subsequent procedures may clear only the newly released EMP. Alternatively, plasmapheresis may eliminate a factor present in TTP plasma that perturbs the endothelium, possibly an antibody or cytokine such as TNFa. In this regard, Wada et al (1993) reported that TNF-a was elevated in the circulation of TTP patients during the onset of TTP. This would be consistent with our finding that TNF-a acts selectively on the microvasculature, eliciting a potent response in MVEC but having little effect on coronary artery EC at the same concentration .
Our study raises the question of the potential role of EMP in TTP. EMP are procoagulant, by virtue of both TF and procoagulant phospholipids (platelet factor three activity) (Combes et al, 1999; Jimenez et al, 2001) . Our finding in vitro that TTP plasma induces release of EMP rich in VWF, and in vivo that EMP in TTP patients also express VWF, suggests a role of EMP in the pathogenesis of TTP. Impaired proteolysis of ULVWF multimers in TTP patients due to the decreased activity of the metalloprotease ADAMTS-13 (a disintegrin and metalloproteinase with thrombospondin motif-1) is currently a favoured hypothesis for the pathogenesis of TTP (Moake, 2002) . Our finding that EMP are carriers of VWF suggest their possible involvement in aberrant VWF processing in TTP.
Studies are underway to clarify the issue of VWF abnormalities as related to EMP in TTP. It has been observed that microparticles, in general, act as activators of leucocytes. We, and others have documented that EMP bind to and activate monocytes, eliciting expression of TF (Jy et al, 2002b; Sabatier et al, 2002b) . Thus, EMP may modulate the inflammatory response of monocytes by regulating the release of cytokines such as TNF-a or IL-1b, which could in turn result in a state of endothelial activation, as seen in TTP.
To summarize: (i) TTP plasma incubated with MVEC in vitro induced the release of EMP with phenotypes indicative of activation, and approximately 60% of them carried VWF; (ii) in parallel clinical studies, EMP levels in patients with TTP correlated well with the severity of TTP. EMP measured in TTP patients carried VWF and exhibited the phenotype of EC activation. The factor in TTP plasma responsible for release of EMP remains to be elucidated. The expression of VWF on EMP further implicates EMP in the pathophysiology of TTP.
